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ABSTRACT
RNA interference occurs by two main processes:
mRNA site-specific cleavage and non-cleavage-
based mRNA degradation or translational repres-
sion. Site-specific cleavage is carried out by
argonaute-2 (Ago2), while all four mammalian
argonaute proteins (Ago1–Ago4) can carry out non-
cleavage-mediated inhibition, suggesting that Ago1,
Ago3 and Ago4 may have similar but potentially
redundant functions. It has been observed that in
mammalian tissues, expression of Ago3 and
Ago4 is dramatically lower compared with Ago1;
however, an optimization of the Ago3 and Ago4
coding sequences to include only the most
common codon at each amino acid position was
able to augment the expression of Ago3 and Ago4
to levels comparable to that of Ago1 and Ago2.
Thus, we examined whether particular sequence
features exist in the coding region of Ago3 and
Ago4 that may prevent a high level of expression.
Swapping specific sub-regions of wild-type and
optimized Ago sequence identified the portion of
the coding region (nucleotides 1–1163 for Ago-3
and 1–1494 for Ago-4) that is most influential for
expression. This finding has implications for the
evolutionary conservation of Ago proteins in the
mammalian lineage and the biological role that
potentially redundant Ago proteins may have.
INTRODUCTION
Argonaute (Ago) proteins are essential for one of the last
steps in the microRNA (miRNA) biogenesis pathway—
the recognition and silencing of target transcripts.
Canonical miRNA biogenesis typically commences with
RNA polymerase II-mediated transcription of primary
microRNA transcripts (pri-microRNAs) in the nucleus,
followed by rapid cleavage by a nuclear microprocessor
complex including Drosha, yielding a precursor miRNA
(pre-miRNA). The pre-miRNA is then transported to the
cytoplasm by Exportin-5, followed by Dicer-mediated
cleavage loading of the short RNA duplex onto an
RNA-induced silencing complex (RISC) by physical asso-
ciation with Ago proteins, and unwinding of the guide and
passenger strands from the RNA duplex (1–5). The RISC
is then brought to a target sequence in the 30-untranslated
region (UTR) of a messenger RNA (mRNA), resulting in
a reduction in protein levels through translational repres-
sion or mRNA de-adenylation and decay (6,7).
Mammals contain four copies of Ago genes:
Ago1–Ago4, also termed eukaryotic initiation factors
2C1–2C4 (EIF2C1, EIF2C2, EIF2C3 and EIF2C4).
While all of these Ago genes have diverged from a single
common ancestral gene (8), three (AGO1, AGO3 and
AGO4) are present as tandem copies in the same orienta-
tion on human chromosome 1p34.3, while AGO2 is
present on its own on human chromosome 8q24.3. The
same pattern of chromosomal arrangement is present in
mice, with the three Ago genes on mouse chromosome
4qD2.2 and one on chromosome 15qD3. Ago2 has
retained the ability to cleave target mRNAs guided
by small-interfering RNAs (siRNAs) in addition non-
cleavage miRNA based gene silencing (9,10). Ago1,
Ago3 and Ago4 most likely have lost this cleavage
function and instead solely rely on a non-cleavage mech-
anism to induce translational repression of target mRNAs
via miRNAs. Argonaute proteins are sequentially divided
into an N-terminal domain, a piwi argonaute and zwille
domain that binds the 30-end of a miRNA, a middle
domain where the 50-end of a miRNA ﬁnds its binding
pocket, followed by an RNase-H-like P-element induced
wimpy testis (PIWI) domain through which Ago2 is able
to induce endonucleolytic cleavage (11–15).
Interestingly, several groups have reported difﬁ-
culties in expressing FLAG-tagged wild-type Ago3 and
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transfection (17,18). We recently noted similar observa-
tions; in controlled transfection studies, over-expression
of FLAG-Ago1 and FLAG-Ago2 led to robust produc-
tion of the transgene-derived protein, whereas much lower
amounts of FLAG-Ago3 and FLAG-Ago4 were detected
(19). However, codon optimization of Ago3 and Ago4
released the repression of Ago3 and Ago4 expression,
leading to levels of FLAG-Ago3 and FLAG-Ago4
proteins that were commensurate with that of FLAG-
Ago1 and FLAG-Ago2 (19). The principle of codon opti-
mization in this context is to replace each triplet codon
with one that represents the most frequently used syn-
onymous codon in the species being studied. For
example, if GTG is the most abundant codon for valine
in mice, it will be selected to code for valine each time, it is
present in the coding sequence. This strategy has been
employed previously to create robust protein expression
and to enable expression in tissues, organisms or cell types
that otherwise do not express the protein [reviewed in
(20)]. Codon optimization was also applied to Ago1 and
Ago2; however, this did not have a notable effect on their
expression levels, which remained at levels comparable
with their respective wild-type sequence constructs (19).
Based on this observation, we sought to determine
whether there are sequence features of Ago3 and Ago4
that may be responsible for the deviation in expression
between wild-type and optimized constructs.
MATERIALS AND METHODS
Codon and sequence optimization
Overviews of and sequence codon optimization for Ago2,
Ago3 and Ago4 have been described previously (19).
FLAG-tagged wild-type argonaute plasmids driven by a
cytomegalovirus promoter were obtained from Addgene
(plasmids 10820, 10822, 10823 and 10824) as described
by Meister and colleagues (16) and were sequenced for
veriﬁcation. A FLAG-tagged GFP construct (Addgene
construct 10825) was used as a negative control.
Basically, sequences were sent to GeneART (Germany)
that examined the sequences and converted each triplet
codon to the codon that is most frequent in
humans. The exception to this was if an AU-rich
element (ARE), a cryptic splice donor or splice acceptor,
or a polyadenylation binding site was present in the
sequence as well; these sequence features were removed
from the ﬁnal coding version. Optimized Ago1 was
generated for the purpose of this study as an additional
basis of comparison to wild-type Ago1. Furthermore, two
constructs were generated by GeneART for Ago3 which
did not optimize the codons, but instead either removed
only regions in the transcript that harbored potential
cryptic splice sites and polyadenylation sites, or those
sites in combination with all ARE sites as well.
Rare codon distribution score
To calculate the cumulative frequency of rare codons a
modiﬁcation of the codon adaptability index was used.
Each codon was scored based on the formula (1 Fi/Fij)
were Fi is the frequency of the codon used in the average
human proteome, and Fij is the frequency of the most
common codon at that particular amino acid. Thus, if
the most frequenct codon is used at a given position, it
will have a score of zero, and the slope of negative values
reﬂects how rare the codons are at each position. The cu-
mulative score was summed across the entire protein.
Protein alignments were done by the ClustalW method.
Northern and western blots
Transfections were performed in 6-well plates with 2mgo f
each human argonaute plasmid co-transfected with 10ng
of pIRESneo GFP as a transfection control. In HEK293
cells, Lipofectamine 2000 (Invitrogen) was used as a trans-
fection reagent. For MEF cell lines, 12-well dishes
were seeded with 1.25 10
4 cells were seeded and 24h
later 500ng of DNA were transfected using TransIT
LT1 transfection reagent (Mirus). In both cases, 48h
post-transfection, total RNA was extracted using Trizol;
protein was extracted using M-PER (Pierce). Mouse
argonaute sequences were transfected in Huh-7 cells
using 800ng of plasmid DNA in 24-well dishes.
Western analysis was performed using antibodies
against a FLAG tag (Sigma, 1:1000) and b-Actin (Santa
Cruz Biotechnology, sc-57778, 1:1000). In total, 10mgo f
protein were loaded. Northerns were performed on a
1% agarose gel using 5mg of Trizol-extracted RNA with
a P32 end-labelled probe against the FLAG sequence,
transferred to a Hybond N+ membrane (Amersham)
and visualized using an autoradiography screen.
Quantitative RT-PCR
Gene-speciﬁc TaqMan probes were ordered from
Applied Biosystems including Hs01084653_m1 for
EIF2C1, Hs00293044_m1 for EIF2C2, Hs00227461_m1
for EIF2C3 and Hs01059731_m1 for EIF2C4. Actin and
Gapdh probes were used for internal normalization. Two
microgram of total RNA were reverse-transcribed using
Superscript II (Invitrogen) in a 20ml reaction volume. For
qPCR reactions, 20ng of cDNA were ampliﬁed on a
7900HT real-time PCR system (Applied Biosystems). To
cross-compare among genes, a standard curve was
generated for each of the argonaute genes using serial di-
lutions of the plasmids used for transfection. The panel of
human RNA samples was obtained from Ambion.
Construct generation
Swapped domain constructs were generated by identifying
restriction sites unique in either wild-type or optimized
sequence and generating primers incorporating these
sites to PCR out the corresponding N-terminal or
C-terminal region. For Ago3, restriction sites that were
present in either wild-type or optimized constructs were
used including PasI at nucleotide 588 and BspEI at
1163. To swap the region after PasI (in bold) the
forward primer, 50-CACCCCCTGGGAGGGGGCAG
was ampliﬁed using the Ago3 wild-type construct with a
reverse primer outside the coding region, 50-GACAGCGA
ATTAATTCCAGCA. This product was digested with
PasI and EcoRI (restriction site present at the terminus
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digested with the same restriction enzymes. The same
approach was used to generate a portion of wild-type
Ago3 in an Ago3 optimized backbone; the T7 forward pri-
mer was ampliﬁed with a reverse primer incorporating a
PasI site, 50-CCCTCCCAGGGGGTGGTCATA, digested
with NotI and PasI and ligated with the Ago3 optimized
construct that was digested with the same enzymes. For
BspEIF, the forward primer to amplify the region after
nucleotide 1163 was 50-TTGGTCCGGAGTGCAAATT
AT, and the reverse primer to amplify the region before
nucleotide 1163 was 50-GCACTCCGGACCAATCTGC
TA. For Ago4, the restriction sites BstEII at nucleotide
780, PmeI at 1494 and BstB1 at 2073 were used. BstEII is
present in both wild-type and optimized constructs, so
these regions were digested directly from the constructs
and swapped. For PmeI, the reverse primer 50-TCAGGT
GTTTAAACATGGGCTCCACGCTGTCG was used
and for BstBI, the forward primer 50-GCCATTCGAAA
GGCCTGCATC was used for ampliﬁcation in Ago4
optimized constructs.
Ago2, Ago3 and Ago4 30-UTRs were appended to the
end of their respective wild-type and optimized constructs
using a PCR-based strategy with an EcoRI restriction
site in the forward primer and a SacI restriction site in
the reverse primer as follows: Ago2UTR_F, 50-CCGCTC
GAGCATGTTTTAGTGTTTAGCGAT; Ago2UTR_R,
50-TCCCCGCGGTACTGCAAACCAGATATATAT;
Ago3UTR_F, 50-GGAATTCATAGTCCAAGTATATT
CTCTG; Ago3UTR_R, 50-TCCCCGCGGTAGTTTGC
CATATTTTATATT; Ago4UTR_F, 50-GGAATTCGAG
TCTCAGAAAAAGAACTCA, Ago4UTR_R, 50-TCCC
CGCGGAGAACTTGCTTTCATCCCA. The UTRs
were also cloned into a PsiCHECK-2 vector (Promega)
for luciferase analysis using a similar set of primers
except that the XhoI restriction site was used in place of
EcoRI in the forward primer and SpeI was used in place of
SacI in the reverse primer.
To generate a construct containing optimized Ago4
with 40nt in the N-terminal sequence of wild-type Ago4,
PCR primers were generated to incorporate the NotI
restriction site (in bold), the ﬁrst 40nt of Ago4 optimized
sequence followed by 10nt of Ago4 wild-type: 50-GCGGC
CGCATGGAGGCGCTGGGACCCGGACCTCCGGC
TAGCCTGTTTCAGCCCCCCAG. This was ampliﬁed
with a reverse primer which included a BstEII site (bold)
that is present in the Ago4 optimized sequence: 50-GGTCA
CCTCCACCTTCAGGCCCCGGATC. A similar strategy
was employed to generate a wild-type Ago4 construct with
40nt of optimized sequence at the extreme N-terminus
using the forward primer 50-GCGGCCGCATGGAAGC
CCTGGGCCCTGGCCCTCCCGCCAGCCTGTTCCA
GCCACCTCG, and the reverse primer which also con-
tained a BstEII restriction site (in bold): 50-GGTCACCTC
AACTTTGAGACCTCTGATT.
To generate Ago4 wild-type sequences with ARE
sequences mutated out, a QuickChange site-directed
mutagenesis kit was used (Stratagene). This converted
two AREs, one starting at nucleotide 351 (ATTTA>CT
TTC) using the forward primer 50-GAGGGTAAAGACC
AAACCTTCAAAGTGTCTGTTCAGTGG (mutations
in bold) and the other at nucleotide 1370 (ATTTA>AC
CTG) using the forward primer 50-CAGAAACAATGTA
GGGAAGACCTGCTAAAGAGTTTCACTGACC.
Mouse Ago1–3 sequences were PCR ampliﬁed with the
following primers using cDNA from C57BL/6 mouse as
template: mAgo1for, 50-AAATATGCGGCCGCATGGA
AGCGGGACCCTCGGGAGCAGC; mAgo1rev, 50-GT
CCGGAATTCTCAAGCGAAGTACATGGTGCGTA
GAG; mAgo2for, 50-AAATATGCGGCCGCATGTACT
CGGGAGCCGGCCCCGTTC; mAgo2rev, 50-GTCCGG
AATTCTCAAGCAAAGTACATGGTGCGCAGTGTG;
mAgo3for, 50-AAATATGCGGCCGCATGGAAATCG
GCTCCGCAGG; mAgo3rev, 50-GTCGCGGATCCTTA
AGCGAAGTACATTGTGCGTAAG. The argonaute
sequences were subsequently cloned into NotI/EcoRI
digested pIRES vector. For mouse Ago4, the sequence
was obtained from RZPD (IRAV p968A07162D), PCR
ampliﬁed using the forward primer 50-AAATATGCGG
CCGCATGGAAATCGGCTCCGCAGG and reverse
primer 50-AAGCGCAATTGGCGATCGCTCAGGCAA
AATACATAGTGTGCTGG, digested with NotI/MfeI
and cloned into NotI/EcoRI-digested pIRES vector.
Luciferase analysis
The PsiCHECK-2 vector system contains both Fireﬂy and
Renilla luciferase for internal normalization purposes.
Luciferase measurements were performed using a dual-
luciferase kit (Promega) using the supplied protocol and
read on a Modulus Microplate Luminometer (Turner
BioSystems).
RESULTS
To determine the overall expression level of Ago mRNA
transcripts, we performed quantitative RT-PCR measure-
ments of all four human Ago mRNA transcripts in
various tissues using TaqMan probes and primers sets
(Figure 1A). These experiments demonstrated that on
average, expression of Ago1 or Ago2 was highest, particu-
larly in skeletal muscle, brain and placenta. Conversely,
Ago3 and Ago4 consistently had a low level of expression
in all tissues examined. We investigated whether this
reduced expression level could result from higher
amounts of rare codons present in Ago3 and Ago4. This
analysis revealed that indeed Ago3 and Ago4 have a
similar and more frequent usage of rare codons
compared with Ago1 and Ago2 (Figure 1B). Notably,
the distribution of rare codons is relatively evenly spaced
throughout the Ago3 and Ago4 proteins, while the fre-
quency for Ago2 is markedly bi-modal with more rare
codons from approximately amino acids 1–400 and more
frequent codons thereafter. A line of best ﬁt for codon
score for Ago2 yielded slopes of  0.174 for the ﬁrst
portion and  0.118 for the second portion (Figure 1B),
though the reason for this bi-modal pattern of codon
usage is presently unclear. Upon examining the ﬁrst 100
amino acids of each Ago protein for rare codons, it is
interesting that Ago3 and Ago4 initially have the fewest
rare codons relative to Ago1 and Ago2, and in particular
the codon score for Ago3 only drops below that of Ago2
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Figure 1. Ago3 and Ago4 consistently have a lower level of expression across various tissues, but a higher cumulative abundance of rare codons.
(A) Relative levels of argonaute mRNA expression in various human tissues. Data represent mean plus standard error of the mean and data points
are normalized to actin using TaqMan probes. A standard curve of argonaute DNA plasmids was constructed for cross-comparison purposes.
Two-way ANOVA signiﬁcance tests with a Bonferroni post-hoc test were performed to compare expression levels between argonaute genes for each
tissue; *P<0.05, **P<0.01, ***P<0.001. (B) The rare codon distribution score across each Ago gene. A rare codon score was calculated from 0 to
 1 at each amino acid position and the cumulative score was plotted for wild-type and optimized Ago1–4. Thus, the lower the score, the more rare
codons are present. (C) The score for the ﬁrst 100 amino acids, boxed in B is shown. (D) The four human argonaute proteins were aligned by the
ClustalW method. Locations where each argonaute used the most frequently used codon for a given amino acid was tabulated in instances where all
four argonautes were identical for a given amino acid (conserved, n=612) and where they differed (non-conserved, n=245–249). (E) Regions where
the four argonautes share the same amino acid, but three use one codon for this and the fourth uses a different codon were identiﬁed, and scored
based on whether codon present in the unique argonaute had an increased codon frequency or a decreased codon frequency. (F) The effect of
transient transfection of individual wild-type (wt) and optimized (opt) Ago constructs on the expression of other argonaute genes using probes that
speciﬁcally recognize only wild-type argonaute genes. The fold change of each argonaute gene increased in a comparable manner, though Ago3 and
Ago4 had lower basal (and thus ﬁnal) absolute levels of expression.
Nucleic Acids Research,2012, Vol.40, No. 8 3707after  80 amino acids (Figure 1C). This may be advanta-
geous to expression of all the argonautes as a ramp of rare
codons at the ﬁrst 50 amino acids has been shown to help
position ribosomes evenly across the beginning of the
transcript, thus enabling smooth translation (21). While
the N-terminus of the protein is relatively more divergent
between argonautes in amino acid conservation, we found
that the choice of optimal versus non-optimal codons did
not depend on amino acid conservation (Figure 1D).
Overall, 612 amino acids were identical between all four
Ago proteins and in these locations, Ago1 used the most
frequent codon 51.6% of the time and Ago2 56.7% of the
time. Conversely, Ago3 and Ago4 used the most frequent
codon only 33.1 and 36.3% of the time, respectively. We
further focused on 213 fully conserved amino acids where
three argonautes use one codon and the last argonaute
uses a different one. These would represent instances
where a mutation has likely occurred solely in the one
unique argonaute, or between Ago2 and the ancestral
gene common to Ago1, Ago3 and Ago4 (8). We would
expect that the mutations would have an equal probability
of changing to a codon that is more frequently expressed
compared with a codon that is less frequent. This is what
is observed for Ago1 with 21 places where the change in
Ago1 led to use of a codon that is more optimal relative to
Ago2–4, and 26 places where the change is less optimal
(Figure 1E). However, for Ago2, there is a 2.35-fold bias
towards more frequent codons while Ago3 and Ago4 have
a 7.29- and 4.10-fold bias toward less optimal codons,
respectively.
To conﬁrm the notion that particular coding sequence
features were responsible for this differential level of
expression of Ago proteins, we generated codon and
sequence optimized constructs of all four human Ago
genes. These constructs were devoid of any RNA-
instability motifs, potential internal cryptic splice sites,
poly-A signals and any other sequence feature that had
the potential to reduce levels of mRNA and protein
expression. In all, 464, 454, 646 and 596nt were altered
in Ago1–4, respectively (18–26% of total nucleotides
changed) (Table 1), leading to sufﬁcient sequence diver-
gence from the wild-type versions that their expression
could no longer be detected with the TaqMan probes
designed for the wild-type Ago mRNAs (Figure 1F).
Northern blot analysis on RNA isolated from HEK293
cells transfected with the individual Ago constructs that
contain the same anti-FLAG probe for each set of
transfected cells conﬁrmed that the level of Ago3 and
Ago4 had a lower level of expression relative to Ago1
and Ago2 (Figure 2A), and that this difference was
alleviated in the codon-optimized constructs. Indeed, this
result was true both for mRNA levels (Figure 2A) and
protein levels (Figure 2B). Transient transfection of
murine FLAG-Ago cDNAs similarly exhibited reduced
expression of mouse Ago3 and Ago4 relative to Ago1
and Ago2 (Figure 2C). The overall distribution of
codons for Ago3 and Ago4 compared with Ago1 and
Ago2 is shown in Supplementary Table S1.
Regulation by one Ago gene on the remaining
argonautes could be envisioned as a mechanism to
maintain a certain window of expression of the various
genes, or to ensure they are expressed only in a particular
temporal or spatial manner. Thus, we explored the possi-
bility that an Ago2-dependent cleavage event was respon-
sible for the low levels of Ago3 and Ago4. We examined
the coding regions of Ago3 and Ago4 for potential
miRNA target sites that may act in an Ago2-dependent
cleavage manner, which generally requires exact comple-
mentarity with nucleotides 1–11 or 2–12 nucleotide seed -
region of a miRNA. We predicted target sites for
several miRNAs in the coding region of Ago3 and
Ago4 (Supplementary Figure S1). This includes
hsa-miR-1913, hsa-miR-497* and hsa-let-7a-2* in Ago3
and hsa-miR-1913, hsa-miR-29a*, hsa-hsa-miR-17*,
hsa-miR-18b* and hsa-mir-769-5p in Ago4. Target sites
for hsa-miR-497* and hsa-miR-33a* were additionally
predicted in Ago2. The genomic interval for hsa-
miR-1913 is not present in the mouse and the mature
hsa-miR-769 is not conserved in the mouse, thus these
miRNAs were excluded as having a potential cleavage
role. However, if Ago2 is responsible for cleavage-based
repression of Ago3 and Ago4, transcript and protein levels
of Ago3 and Ago4 should be elevated in Ago2
 /  cells,
since Ago2 is the only mammalian Ago that has the po-
tential to cleave target mRNAs. When constructs express-
ing the Ago genes were transfected into mouse embryonic
ﬁbroblast (MEF) cells that had a disrupted and inactive
Ago2 transcript (9), the level of expression of wild-type
Ago3 and Ago4 remained low to non-detectable, while
codon-optimized Ago3 and Ago4 levels were also un-
changed (Figure 2D). This indicates that putative
cleavage-mediated regulation of the transcripts is not
responsible for the low levels of Ago3 and Ago4, though
it is still possible that miRNA sites exist for
Table 1. Sequence features in wild-type (wt) versus optimized (opt) argonaute constructs
Ago1wt Ago1opt Ago2wt Ago2opt Ago3wt Ago3opt Ago4wt Ago4opt
Nucleotide changes 464 454 646 597
Nucleotides changed (%) 18 18 26 24
Codon adaptability index 0.80 0.98 0.80 0.97 0.71 0.97 0.73 0.97
GC content (%) 54 62 56 64 45 64 47 64
Prokaryotic inhibitory motifs nd nd 5 0 7 0 2 0
Polyadenylation sites 0 0 1 0 1 0 2 0
Consensus splice donors nd nd 2 0 3 0 2 0
ARE RNA-instability motifs 1 0 1 0 6 0 6 0
nd, not determined.
3708 Nucleic Acids Research, 2012,Vol.40, No. 8non-cleavage-based regulation of the mRNA transcripts.
We have shown that miRNAs are ineffective at targeting
coding regions unless their binding sites are immediately
downstream of rare codons (22). While certain infrequent
codons are present more often in Ago3 and Ago4, most
notably GTA encoding Valine (Supplementary Table S1),
a preponderance of miRNA sites following these rare
codons was not observed. In addition, transient transfec-
tion of FLAG-HA tagged human Ago expression cassettes
into HEK293 cells resulted in an increase in the transcript
level of the expressed Ago and did not have an effect on
the endogenous level of any of the Ago family members,
apart from a slight increase in Ago1 detection levels after
transfection of Ago3 (Figure 1D).
Another means by which particular mRNAs can be rap-
idly degraded and turned over is through the presence of
RNA-instability motifs within their sequence. While these
elements are typically concentrated in the 30-UTRs of
genes, they theoretically could have the same effect if
present within the coding region (23,24). For instance,
one miRNA that is involved in this process is miR-16
which, by virtue of its AU-rich sequence and facilitated
by tristetraprolin (TTP) is able to recruit the RISC
complex to AU-rich sequence elements and induce rapid
mRNA turnover (25). Notably, when the coding
sequences of Ago3 and Ago4 were examined, a prepon-
derance of AREs were present, six each in Ago3 and
Ago4, relative to only one each present in Ago1 and
Ago2 (Table 1). These became key targets of our investi-
gation. In order to address the potential inﬂuence of these
AREs on Ago expression levels, additional Ago3 con-
structs were engineered in which only the regions where
the AREs were present were converted to the codon-
optimized sequence and the remainder of the DNA
Figure 2. Ago3 and Ago4 mRNA and protein expression is decreased dramatically relative to Ago1 and Ago2 while this expression difference is
alleviated by codon and sequence optimization. (A) Northern blot of argonaute wild-type or codon-optimized Trizol-extracted RNA samples from
293 cells loaded in duplicate shows reduced expression of Ago3 and Ago4. The blot was stripped and re-probed for 28S as a loading control.
(B) Western blot analysis from FLAG-tagged wild-type and optimized human Ago sequences transiently transfected in HEK293 cells shows that
protein levels correlate with the mRNA levels in A. Data represent mean±SEM, quantiﬁed relative to b-actin and normalized to Ago1wt.
(C) Western blot of FLAG-tagged murine Ago1–4 cDNA constructs transiently transfected in Huh7 cells displayed a similar proﬁle of reduced
level of expression of Ago3 and Ago4 relative to Ago1 and Ago2. (D) Absence of Ago2 does not inﬂuence expression of Ago3 and Ago4. Ago2 null
MEF cells were transfected with the same wild-type or optimized plasmids, co-transfected with a GFP plasmid. (E) Western blot quantiﬁcation of
Ago3 constructs that have an abolition of internal potential splice site sequences and all AREs does not account for the reduced protein expression of
wild-type relative to optimized sequences. Bands are quantiﬁed relative to b-actin and normalized to Ago3opt levels. (F) Western blot quantiﬁcation
of Ago4 constructs normalized to Ago4opt expression. Wt_optNterm represents modiﬁcation of only the ﬁrst 40nt of Ago4wt to corresponding
Ago4opt sequences. Opt_wtNterm contains an wild-type sequence of Ago4 for the ﬁrst 40nt and an optimized sequence therafter. ARE1 and ARE2
represent site-directed mutagenesis of two individual AREs in wild-type Ago4 sequence at nucleotide positions 351 and 1370, respectively.
Nucleic Acids Research,2012, Vol.40, No. 8 3709sequence was identical to wild-type Ago3. As an addition-
al test, both cryptic splice donors and acceptors as well as
weak polyadenylation binding protein sites were also
converted to optimized sequence to prevent the potential
generation of truncated transcripts or proteins which
could subsequently be degraded and no longer detected.
This resulted in changes in 13 sequence motifs totaling
37nt. It is important to point out here that this new
Ago3 contained considerably fewer changes than the
total of 646 that were modiﬁed in the original codon-
optimized version (see above). Remarkably however, as
shown in Figure 2E, the elimination of these AREs and
potential splice or polyadenylation sites had no effect on
the expression of the Ago3 construct as compared to
wtAgo3. Site-directed mutagenesis of two of the AREs
in the Ago4 construct similarly had no effect on its
expression relative to Ago4 (Figure 2F). Thus we were
able to exclude RNA-instability motifs as the cause of
the differential expression among the Ago proteins.
We next asked whether a particular domain of the Ago3
or Ago4 transcript was responsible for their differential
levels of expression relative to codon-optimized versions,
or was a global distribution of a particular feature, such as
rare codons, responsible. To address this question, we
generated chimeric constructs whereby sequences of the
wild-type Ago3 were swapped with sequences of optimized
Ago3 (Figure 3A). Similar domain swapping was also per-
formed for Ago4, and the resulting effect on mRNA and
protein level was analysed (Figure 3B). As seen in
Figure 3, the region that was most responsible for Ago3
expression was contained within nucleotides 1–1163 at the
N-terminal half of the gene. However, when this region
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Figure 3. A swap of Ago wild-type (wt) and optimized (opt) sequences reveals the N-terminus of both Ago3 and Ago4 are critical for differential
expression. (A) Regions of wild-type and optimized Ago3 and Ago4 constructs were swapped to create chimera proteins as depicted (e.g. 3wt1163opt
contains the ﬁrst 1163nt of wild-type Ago3 followed by the remaining C-terminal optimized Ago3 sequence). Northern (B) and western (C) results
indicate that a sequence motif in the N-terminal portion of the protein is responsible for this differential expression. (D) Rare codon cumulative
scores for Ago3 wild-type, optimized and swapped domain constructs were compared as in Figure 1C. Samples with high levels of expression were
dark gray while those with low levels of expression were light gray; overall the rare codon burden did not correlate with expression of the construct.
(E) A similar rare codon cumulative frequency score was plotted for Ago4 wild-type, optimized and swapped domain constructs, with high-expressing
samples in dark gray and low-expressing samples in light gray.
3710 Nucleic Acids Research, 2012,Vol.40, No. 8was further narrowed down to include only nucleotides
1–588 of either wild-type or optimized Ago3 combined
with nucleotides 589–2580 of the other construct, the
enhanced expression effect was ameliorated, as the
overall mRNA and protein levels became comparable to
those observed with the wild-type sequence. Thus, though
the precise region involved in controlling expression levels
cannot be deﬁnitively elucidated, it does appear to involve
features that are spread throughout the ﬁrst half of the
gene. For Ago4, again the critical region that determines
expression was present in the ﬁrst 780nt of the gene. Both
mRNA and protein levels were repressed when the ﬁrst
780nt were from Ago4 wild-type sequence and the
remainder were codon and sequence optimized, while
high mRNA and protein levels were present in the recip-
rocal situation when nucleotides 1–780 were codon and
sequence optimized and the rest of the gene remained
wild-type (Figure 3B and C). The rare codon score was
also calculated for these chimeric constructs and
compared with wild-type and optimized Agos. In both
Ago3 (Figure 3D) and Ago4 (Figure 3E), the ﬁnal
codon score did not correlate with expression levels of
each construct. This indicated that it was not the overall
codon burden that was implicated but instead rare codons
or related sequence features within speciﬁc regions.
Sequences at the extreme 50-terminus of the coding
region have also been implicated in translational
dynamics, aiding in mRNA stability and ribosomal accel-
eration through the transcript (26,27). Notably, we found
that the extreme N-terminus of each coding region was
not responsible as swapping the initial 40nt of wild-type
Ago4 with the optimized sequence and optimized Ago4
with an initial wild-type 40nt did not alter expression
(Figure 2F). In addition, the overall secondary structure
at the translation initiation site was not dramatically
altered when sequences were optimized (Supplementary
Figure S2). This correlated with the observation that
rare codon distribution was not markedly different for
Ago1–4 at the N-terminus of each gene (Figure 1D).
Each of these constructs that were generated in this
study contained only the coding region of the Ago
genes, raising the possibility that sequence elements in
the 30-UTR of each gene could inﬂuence Ago3 and Ago4
expression. To help address this, we examined the effect of
appending the 30-UTR of Ago2, Ago3 and Ago4 after
each gene’s respective coding sequence. However, this
did not have an effect on protein expression
(Figure 4A). In addition, the effect of each 30-UTR on
luciferase expression in a ﬁreﬂy/renilla dual luciferase
reporter system was similarly unchanged from a control
sequence (Figure 4B), indicating that adding back the
30-UTR does not over-ride the signals observed that are
speciﬁc to the coding region.
Finally, another factor that could potentially inﬂuence
efﬁciency of translation and gene expression is RNA sec-
ondary structure (28). We used a recently published RNA
folding algorithm (29), which considers the entire
ensemble of possible RNA structures for a given
sequence, to assess differences in predicted RNA structure
between the wild-type and optimized versions of each
Ago. We found that the overall RNA structure is
slightly less correlated between wild-type and optimized
sequences for Ago3 (correlational coefﬁcient, CC=0.15)
and Ago4 (CC=0.21) than for Ago1 (CC=0.22) and
Ago2 (CC=0.24). This result suggests that while second-
ary structure may be a contributor to the expression dif-
ferences, and as such merits further investigation outside
of the scope of this study, it is likely not the sole factor.
DISCUSSION
We explored several coding region features that may
account for the differential gene and protein expression
of Ago3 and Ago4 compared to Ago1 and Ago2. Of
these features, we experimentally excluded the possibility
that AREs in the coding region, despite being more preva-
lent in Ago3 and Ago4 relative to Ago1 and Ago2, were
responsible for the observed differences. In addition, the
overall codon distribution across the genes did not seem to
be critical for expression. Instead, codon distribution or
other related sequence features in the N-terminal regions
(but not the direct N-terminus itself) appear to have the
greatest impact on sustained levels of Ago3 and Ago4
expression. The intermediate level of expression observed
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Figure 4. Addition of argonaute 30-UTRs does not inﬂuence or rescue a difference in expression between wild-type and optimized constructs.
(A) The 30-UTR of Ago2 was appended to the coding sequence of wild-type and optimized Ago2, Ago3 or Ago4. No inﬂuence on expression
levels was observed after western analysis. FLAG-tagged argonaute constructs co-transfected with FLAG-GFP were detected using an anti-FLAG
antibody and also probed for actin for normalization purposes. (B) Expression of FLAG-GFP incorporating the 30-UTRs of Ago2, 3, 4 or none
(control). Addition of the UTR after the Renilla luciferase reporter gene had no inﬂuence on expression as measured by relative levels of renilla to
ﬁreﬂy luciferase in 293 cells.
Nucleic Acids Research,2012, Vol.40, No. 8 3711after domain swapping indicates that more than just one
sequence motif is responsible. This makes it prohibitive to
determine the relevant contribution of each of the individ-
ual sequence motifs. However, the ﬁnding does exclude
the possibility that rare codons across the whole coding
region of the gene are responsible. Examination of the
coding region of these genes did reveal that certain rare
codons, most notably those for valine (GTA), were
present in greater frequencies in Ago3 and Ago4 relative
to Ago1 and Ago2 (Supplementary Table S1); however,
the fairly uniform distribution of these rare codons
throughout Ago3 and Ago4 is inconsistent with our
results, which suggested that the N-terminal region was
the most critical for determining expression. Another im-
portant distinction relates to the level of RNA expression
versus protein abundance. We have observed that both the
RNA and protein levels of Ago3 and Ago4 are dimin-
ished. The level of rare codons, while predominantly
inﬂuencing protein expression can also impact RNA sta-
bility. Pausing of a ribosome at rare codon clusters can
increase the accessibility of RNA-instability elements to
degrade mRNA (30,31). Because the cDNA constructs
were cloned into the same expression vector, DNA
features in promoters and introns such as transcription
factor binding sites, histone and DNA methylation
marks, insulators and enhancers do not play a role in
this change of expression. Further, pre-mRNA splice
factors would not be inﬂuential in this system.
A recent study performed HITS-CLIP analysis and
identiﬁed miRNA target sites in the P13 mouse brain
(32), including miR-9, miR-153 and let-7 sites in the
Ago2 coding region and a let-7 and miR-9 site in the
coding region of Ago3. However, Ago1 and Ago4 did
not have annotated miRNA target sites. While this target-
ing may represent a tissue-speciﬁc phenomenon, particu-
larly for miR-9 an abundant miRNA in the brain, the
presence of potential target sites in the coding region of
these argonaute transcripts is still intriguing. The fact that
no miRNA target sites were present in Ago4, and the
observation that the only miRNAs that displayed
evidence of binding in Ago3 were also found in Ago2
argues against miRNA targeting of the coding region as
the primary mechanism for differential regulation of
expression of Ago3 and Ago4 relative to Ago1 and
Ago2. We noted variable expression of Ago2 depending
on the tissue examined (Figure 1A). Since, we observed no
change in Ago2 protein levels upon its codon and
sequence optimization, it suggests that additional factors
apart from rare codons and RNA sequence features are
still responsible for the expression of this gene.
Maintaining a high level of Ago3 and Ago4 through
these codon-optimized constructs could help indicate a
distinct role for these genes with respect to the other
argonautes. However, the possibility remains that the
two Ago genes are being evolutionarily phased out.
While a formal analysis of the nucleotide substitutions
that have taken place over the evolution of the genes
could help address this issue, the lower level of expression
of both Ago3 and Ago4 could represent a decreased de-
pendency for three mammalian argonaute genes.
Alternatively, sequence elements and rare codons may
have accumulated in Ago3 and Ago4 to dampen their ex-
pression in certain contexts. The high frequency of rare
codons in Ago3 and Ago4 is conserved across species,
which is suggestive of evolutionary constraint due to a
heretofore unknown functional importance.
Another issue to address is the overall beneﬁts and
perils of codon and sequence optimization. There is no
guarantee that an optimized version of a gene will have
a sustained level of expression in an endogenous scenario,
or that such an effect will actually be beneﬁcial for a cell.
Indeed, certain sequence elements encoded in the mRNA
may positively or negatively regulate Ago3 and Ago4
expression. These sequence motifs likely would be
abrogated when generating codon-optimized constructs.
In addition, by constantly using the most frequent
codon at each position, the anticodon-containing tRNAs
that recognize this codon could become limiting particu-
larly in repetitive stretches of identical codons. Our la-
boratory has been interested in maintaining high levels
of argonaute expression to prevent saturation of RNAi
components which can cause lethality in mice (33).
While we have evidence that maintaining high levels of
Ago2 is crucial for preventing this toxicity (19), the
levels of other argonaute proteins may also aid in circum-
venting this toxicity. In this context, administering
optimized Ago3 or Ago4 in conjunction with short-
hairpin RNAs (shRNAs) could release the burden of a
saturated RISC complex and enable both exogenous
Ago2-mediated cleavage of target mRNAs while main-
taining the ability for endogenous miRNA pathways to
operate unperturbed. Another possibility is that the
relative ratios of the various Agos may be important for
maintaining a balance of various miRNAs which are
RISC loaded (active) versus unloaded (inactive) under
different physiological cellular conditions. The reasons
as to why Ago3 and Ago4 have low levels of expression
are presently unclear; however, we can conclude that
certain sequence features of Ago3 and Ago4, present in
the ﬁrst half of the mRNA are responsible for their
endogenous expression levels. Further studies will likely
reveal more insights into the biological role of the
non-cleaving Ago proteins in mammalian systems.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online:
Supplementary Table 1 and Supplementary Figures
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